Tuesday, November 17, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
How to earnPaparazzi InkHolder perksLeaderboardAssignmentsContestsLeagueCity
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsCity LeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundToken utilityRobinhood Chain launchesRobinhood Chain projectsPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 56

FDA clears Biocon's Perjeta biosimilar, but US shelves wait until 2028

Biocon won FDA approval for Pebrilzo (pertuzumab-qcay), a biosimilar to Perjeta, covering HER2-positive breast cancer from metastatic to early-stage disease. The catch: a patent settlement with Genentech pushes the earliest US launch to the third quarter of 2028.

By the Paparazzi desk November 16, 2026 · 7:00 PM · targetedonc.com · 0 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: targetedonc.com.
  • The source published it on Nov 16, 2026 at 7:00 PM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

Biocon Limited has scored FDA approval for pertuzumab-qcay, sold as Pebrilzo, a biosimilar of Genentech's Perjeta. The agency cleared it for adults with HER2-positive breast cancer, spanning both metastatic and early-stage settings, Biocon announced on November 16, 2026.

In metastatic disease, Pebrilzo is indicated alongside trastuzumab (Herceptin) and docetaxel for patients who have not yet received anti-HER2 therapy or chemotherapy for metastatic disease. It is also approved in two early breast cancer settings: neoadjuvant use with trastuzumab and chemotherapy for locally advanced, inflammatory or early-stage tumors larger than 2 cm or node-positive disease as part of a complete regimen, and adjuvant treatment for early-stage patients at high risk of recurrence. Pertuzumab works as a monoclonal antibody that binds HER2 and blocks it from pairing with other HER family receptors, disrupting growth and survival signaling.

Sponsored

Biocon said the approval rested on structural and functional characterization, analytical similarity assessments and comparative clinical pharmacokinetic data, which it reported showed high similarity to the reference product with no clinically meaningful differences in quality, safety, efficacy or immunogenicity.

The FDA nod does not mean a fast US rollout. Under a global settlement and license agreement with Genentech announced October 14, 2026, which resolved disputes across the United States, Canada and other jurisdictions, Biocon named the third quarter of 2028 as the earliest licensed US launch date for Pebrilzo. The company put the earliest licensed launch in the European Union and United Kingdom at the first quarter of 2027, pending regulatory approval. The EMA's Committee for Medicinal Products for Human Use backed the 420-mg/14-mL infusion concentrate with a positive opinion in September 2026.

Pebrilzo arrives late to a race already underway. The FDA approved pertuzumab-dpzb (Poherdy) on November 13, 2025, making it the first Perjeta biosimilar and designating it interchangeable, which allows pharmacy-level substitution under state law. Shanghai Henlius' HLX11 is also in play, with the FDA accepting its biologics license application in February 2025.

HER2-positive disease accounts for roughly 15% to 20% of breast cancers, and the American Cancer Society estimates 321,910 people in the US will be diagnosed with invasive breast cancer in 2026. Biocon is also pursuing biosimilars to trastuzumab/hyaluronidase, nivolumab (Opdivo) and pembrolizumab (Keytruda). 'The U.S. FDA approval of Pebrilzo, our biosimilar pertuzumab, marks another significant milestone in Biocon's journey to expand access to high-quality biosimilars,' said Shreehas Tambe, CEO and managing director of Biocon Limited.

TopicsBiocon Limited · Pebrilzo · pertuzumab-qcay · Genentech · Perjeta · Poherdy · Shreehas Tambe · FDA

Share

Source: targetedonc.com

Written by AI from verified reporting.

More stories

  • Health & science 1 hour ago · theepochtimes.com · 0 views
    FDA Refuses to Approve Akeso-Summit Lung Cancer Drug After Survival Miss
  • Health & science 2 hours ago · healthandme.com · 0 views
    Europe approves Revolution Medicines' RAS-blocking pancreatic cancer pill
  • Health & science 2 hours ago · wdsu.com · 0 views
    FDA Greenlights First Treatment for Deadly Sanfilippo Syndrome
  • Health & science 3 hours ago · finance.yahoo.com · 0 views
    Novartis' Cosentyx wins FDA nod as first anti-IL-17 biologic for PMR
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.